Mirror Biologics Overview
Mirror Biologics is an international biopharmaceutical company specialized in development and manufacturing of next generation immunotherapy products where the active ingredients are living immune cells. Its technology originally spun out from Hadassah-Hebrew University Medical Center in Jerusalem. The company operates a 21 CFR 1271-compliant blood donor and cell processing center and conduct research and development on the design and testing of novel bioreactors and commercial manufacturing systems. Its next generation immunotherapy programs aim to harness the power of the human immune system to treat and prevent disease. The company has developed a patented immune cell, called AlloStim®, with powerful immunomodulatory properties that is used to educate and modify a patients’ own immune system to enable it to identify and destroy cancers and infectious organisms and to reprogram immune systems weakened by age or chronic infection. Its immunomodulatory vaccine development programs are based upon its novel Mirror Effect® technology platform which is able to imprint a re-programmed immune response over an existing failed immune response of a diseased or elderly patient. This novel technology platform expands the indications and type of patients that might benefit from immunotherapy approaches beyond first generation CAR-T and checkpoint inhibitor approaches. Mirror Biologics acquired all the assets of Immunovative Therapies.
Cumulative Funding Raised Over Time ($)
$12.0MJan 2012
$42.0MJan 2022
$42.5MMay 2006
Latest News
Mirror Biologics, Inc. Announces Initiation of AlloStim® Phase IIB Clinical Trial (STIMVAX) in Patients with Metastatic Colorectal Cancer - PR.com
growth-positive
Israeli Company Hopes Universal Anti-Viral Vaccine Will Protect Elderly From COVID-19 - The Media Line
Jerusalem-based Immunovative Therapies is conducting clinical trials in the US for its experimental immunotherapy drug, AlloStim. The drug, which is designed to reverse the aging process of an elderly person’s immune system, has received approval from the US Food and Drug Administration (FDA) for the trials. The companys CEO, Michael Har-Noy, believes the drug could help the elderly cope with a wide range of illnesses, including COVID-19 and metastatic cancers. The company is currently seeking investors to help bring the drug to market.
Investment
growth-positive
Immunovative Therapies and Mirror Biologics Announce US FDA Clearance of a Universal Anti-Viral Vaccine Phase I/II Clinical Trial for Healthy Elderly Adults
Mirror Biologics, Inc., the commercial development arm of Immunovative Therapies, Ltd., has received clearance from the FDA for its Phase I/II universal virus vaccine clinical trial. The trial will test the companys lead experimental drug, AlloStim®, as an anti-viral prophylaxis drug specifically targeted to protect the elderly. The vaccine technology is designed to protect against any type of viral infection without prior knowledge of the viral structure and is intended to work in the weakened immune systems of the elderly. The trial will involve 40 healthy adults over the age of 65, who will receive multiple injections of AlloStim® and have their blood challenged with live viruses to determine the effectiveness of the vaccine. Mirror Biologics plans to scale up production if the vaccine demonstrates safety and efficacy.
Customers
growth-positive
Mirror Biologics and Immunovative Therapies announce publication of the technical rationale for development of a universal anti-viral vaccine targeted
Mirror Biologics, Inc. announces the publication of a manuscript describing a new approach for vaccine development for the elderly. The technology called AlloPriming aims to prime the elderly immune system to respond to viruses in the same manner as a healthy younger adult immune system would respond. The manuscript proposes that the successful remodeling of the aging immune system may prevent age-related diseases. The technology could provide ongoing protection against diseases like COVID-19 even if the virus mutates. Mirror Biologics, Inc. is the commercial development arm of Immunovative Therapies, Ltd.
Customers
growth-positive
Vaccine to protect from any viral infection
Mirror Biologics Inc., a subsidiary of Immunovative Therapies Ltd., has presented a novel vaccination concept that aims to protect risk groups from new SARS-CoV-2 variants. The companys approach, called AlloPriming, focuses on addressing viral evolution. It involves a series of injections of bioengineered Th1-cells to provide protection against future viral infections, including COVID-19 and future variants. The technology primes the immune system of elderly adults to respond to viruses in the same way as a healthy younger adult immune system. Mirror Biologics is preparing for Phase I/II clinical testing in healthy adults over 50 years old. The approach is seen as complementary to current vaccination strategies. Traditional vaccines may not provide long-term protection against rapidly mutating pathogens and could potentially make them more aggressive. If successful, AlloPriming could provide a single series of shots to protect against the current and future pandemics.
CustomersPartners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $42.5M |
| Last funding | $30M |
| Stage | A |
| Rounds | 3 |
| Investors | 3 |
Team Members
1
Employees: 1-10
Web & Social Links
| Website | www.mirrorbio.com/ |
| Careers | Careers page |
Locations
Agudat Sport HaPo'el Road 1, Jerusalem, Israel
Tampa, FL, USA
Malaysia
Bangkok, Thailand
Photos & Videos
No files yet
Mirror Biologics Business
Business models
B2B
Product stage
Clinical Trial
Employees
1-10
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesLife SciencesBiotechnologyPharmaceuticalsCore Technology
BiologicalsCellsTags (12)
biotechnologycancerinfectious-diseasecell-therapyoncologyimmunotherapybiopharmaceuticalimmunologystem-cellspatientspharma-companiesvaccinesGeographic Markets
CanadaUnited StatesMirror Biologics Financials
$42.5M
Total funding
Undisclosed
Capital raised
$30M
Last funding
A
Funding stage
3
Total rounds
3
Investors
Cumulative Funding Raised Over Time ($)
$12.0MJan 2012
$42.0MJan 2022
$42.5MMay 2006
Private Equity Funding
A Round
Jan 2022
$30M
Undisclosed Investor(s)
Undisclosed Round
Jan 2012
$12M
Misgav Technology Center, The Trendlines Group
Seed
May 2006
$500K
Mirror Biologics Lifecycle
Cumulative Funding Raised Over Time
$12.0MJan 2012
$42.0MJan 2022
$42.5MMay 2006
All Events
A Round
Jan 2022
$30M
Undisclosed Investor(s)
Undisclosed Round
Jan 2012
$12M
Misgav Technology Center, The Trendlines Group
Seed
May 2006
$500K
Mirror Biologics News
14 articlesMirror Biologics, Inc. Announces Initiation of AlloStim® Phase IIB Clinical Trial (STIMVAX) in Patients with Metastatic Colorectal Cancer - PR.com
growth-positive
Israeli Company Hopes Universal Anti-Viral Vaccine Will Protect Elderly From COVID-19 - The Media Line
Jerusalem-based Immunovative Therapies is conducting clinical trials in the US for its experimental immunotherapy drug, AlloStim. The drug, which is designed to reverse the aging process of an elderly person’s immune system, has received approval from the US Food and Drug Administration (FDA) for the trials. The companys CEO, Michael Har-Noy, believes the drug could help the elderly cope with a wide range of illnesses, including COVID-19 and metastatic cancers. The company is currently seeking investors to help bring the drug to market.
Investment
growth-positive
Immunovative Therapies and Mirror Biologics Announce US FDA Clearance of a Universal Anti-Viral Vaccine Phase I/II Clinical Trial for Healthy Elderly Adults
Mirror Biologics, Inc., the commercial development arm of Immunovative Therapies, Ltd., has received clearance from the FDA for its Phase I/II universal virus vaccine clinical trial. The trial will test the companys lead experimental drug, AlloStim®, as an anti-viral prophylaxis drug specifically targeted to protect the elderly. The vaccine technology is designed to protect against any type of viral infection without prior knowledge of the viral structure and is intended to work in the weakened immune systems of the elderly. The trial will involve 40 healthy adults over the age of 65, who will receive multiple injections of AlloStim® and have their blood challenged with live viruses to determine the effectiveness of the vaccine. Mirror Biologics plans to scale up production if the vaccine demonstrates safety and efficacy.
Customers
growth-positive
Mirror Biologics and Immunovative Therapies announce publication of the technical rationale for development of a universal anti-viral vaccine targeted
Mirror Biologics, Inc. announces the publication of a manuscript describing a new approach for vaccine development for the elderly. The technology called AlloPriming aims to prime the elderly immune system to respond to viruses in the same manner as a healthy younger adult immune system would respond. The manuscript proposes that the successful remodeling of the aging immune system may prevent age-related diseases. The technology could provide ongoing protection against diseases like COVID-19 even if the virus mutates. Mirror Biologics, Inc. is the commercial development arm of Immunovative Therapies, Ltd.
Customers
growth-positive
Vaccine to protect from any viral infection
Mirror Biologics Inc., a subsidiary of Immunovative Therapies Ltd., has presented a novel vaccination concept that aims to protect risk groups from new SARS-CoV-2 variants. The companys approach, called AlloPriming, focuses on addressing viral evolution. It involves a series of injections of bioengineered Th1-cells to provide protection against future viral infections, including COVID-19 and future variants. The technology primes the immune system of elderly adults to respond to viruses in the same way as a healthy younger adult immune system. Mirror Biologics is preparing for Phase I/II clinical testing in healthy adults over 50 years old. The approach is seen as complementary to current vaccination strategies. Traditional vaccines may not provide long-term protection against rapidly mutating pathogens and could potentially make them more aggressive. If successful, AlloPriming could provide a single series of shots to protect against the current and future pandemics.
CustomersPartners
growth-negative
Navigating the Challenges of Cell-Based Immunotherapies
The article discusses the challenges and future prospects of cell-based immunotherapy. It highlights the limited mainstream use of cell therapies and the need to address pitfalls in their distribution and manufacturing. The article also explores the relative advantages of the allogeneic and autologous approaches in cell therapy. Key topics include the cost of goods, supply chain manufacturing, and reducing the cost of cellular therapy. The article suggests that the autologous model may be difficult to commercialize and that allogeneic treatments resemble traditional biologics. Sigilon Therapeutics is mentioned as one of the companies involved in cell therapy. The impact of the article on the company is classified as growth-negative.
CustomersPartnersInvestmentAcquisitionManagement Changes
growth-positive
Could an immunotherapy treatment from Israel cure cancer?
Immunovative Therapies, a Jerusalem-based startup developing an immunotherapy treatment for cancer, has seen significant growth in the past decade. The company has conducted numerous clinical trials, opened branches in California, Arizona, and Thailand, and raised $35 million. The recent publicity surrounding immunotherapy pioneer Jim Allison, who won the Nobel Prize in chemistry, has further boosted the companys prospects. Immunovative Therapies is focusing on tackling bowel, colon, and liver cancers, as well as developing a cancer vaccine. The company is currently testing its treatment on HIV-positive patients, with promising results. Immunovative plans to raise up to $30 million in 2019 for phase III studies and is considering an IPO in the future.
InvestmentExpand
growth-positive
Immunovative Therapies to Present at Biotech Showcase™ 2019 in San Francisco
Immunovative Therapies, Ltd. will present at Biotech Showcase 2019. The company develops next-generation immunotherapy treatments for cancer and has completed Phase II clinical development for three products. The lead product, StimVax, is being advanced to Phase IIb clinical trials. Immunovative Therapies has also formed a subsidiary, Mirror Biologics, Inc., to develop automated bioreactor systems for the mass production of living cell therapies. The company aims to provide affordable and effective treatment options for patients suffering from metastatic cancer.
PartnersExpand
growth-positive
Deep Dive: Immunovative Therapies' Next-Generation Cancer Vaccine Could Change the Game BioSpace
Israeli biopharmaceutical company Immunovative Therapies has developed Mirror Effect® technology, which has shown promise in turning cold tumors into hot tumors, making immunotherapy more effective. The technology reverses the tumors immune suppression effects and educates the immune system to recognize tumor cells as foreign. Immunovative Therapies has three ongoing Phase II clinical trials for cancer vaccines that use Mirror Effect® technology. The vaccines have shown significant tumor reduction and increased survival rates in patients with head and neck cancer and hepatocellular carcinoma. The vaccines are well-tolerated and affordable, making them a potential widely available immunotherapy treatment option. Immunovative Therapies is planning randomized, controlled Phase III trials for drug distribution licensing.
CustomersInvestment
growth-positive
Clinical Trial to Assess Next Generation Immunotherapy in...
Immunovative Therapies has begun a Phase 2b clinical trial for its cancer vaccine CryoVax, a third-line therapy for patients with metastatic colorectal cancer who are resistant to chemotherapy. The trial has already dosed its first patients, and enrollment is expected to be completed by the end of July 2017. CryoVax is designed to treat the 85% of patients with metastatic colorectal cancer who do not respond to immunotherapies. The trial is being conducted by Banner MD Anderson Medical Center in Phoenix, Arizona, a partner of MD Anderson Cancer Center in Houston, Texas.
Partners
growth-positive
CryoVax(R) : Next Generation Immunotherapy for Metastatic Colorectal Cancer Begins USA Phase IIb Clinical Trial
Immunovative Therapies, Ltd., on behalf of its subsidiary, ImmunoCare, Ltd., has announced the start of a Phase IIb study of CryoVax, a next generation immunotherapy cancer vaccine product, for patients with chemotherapy-refractory metastatic colorectal cancer (mCRC). The trial is being conducted by Banner MD Anderson Medical Center, in Phoenix, AZ, which is partnered with the University of Texas MD Anderson Cancer Center in Houston, TX. The first volunteers have received their initial vaccine doses and enrollment is expected to be completed by the end of July 2017.
InvestmentPartnersCustomers
growth-positive
Immunovative Therapies to go public through US reverse merger
Immunovative is taking its subsidiary Immunovative Clinical Research Inc. public through a reverse merger with Novo Energies Corporation. The company is developing a bioengineered cell product called AlloStim for the treatment of colorectal and breast cancer. The successful clinical development of AlloStim could lead to fast-track market approval and significant revenue potential. Immunovative has conducted an FDA trial on colorectal cancer patients, with positive results. The company has been financed by private investors and grants. The merger with Novo Energies is expected to result in Immunovative owning 83% of the merged company.
Public TradingInvestment
growth-positive
CryoStim™ Cancer Treatment to Begin FDA Clinical Trials September 1, 2009
Immunovative Therapies Ltd. has announced that its experimental product, CryoStim, has been cleared by the FDA to begin human clinical trials. CryoStim is based on Mirror Effect technology, which aims to provide the same anti-tumor effect as allogeneic bone marrow transplant procedures without the lethal toxicity or need for a matched donor. The company believes that if successful, this therapy could eliminate all tumor cells and prevent recurrence.
InvestmentExpand
growth-positive
'Angry' cell treatment harnesses power of immune system to destroy cancer cells
Israeli biopharmaceutical start-up Immunovative Therapies is developing a potentially revolutionary immunotherapy drug called AlloStim, which incorporates living immune cells to stimulate the bodys immune system to fight cancer cells. The drug has been successfully tested in animal trials, and Phase I/II clinical trials on patients with advanced blood cancer are set to begin soon. The company aims to address the limitations of conventional cancer therapies and provide a new treatment option. Immunovative Therapies plans to focus on patients with advanced blood cancer initially and expand to other types of cancer in the future. The company is seeking fast-track approval from the FDA for its drug. Immunovative Therapies has raised $1.2 million from angel investors and is currently raising an additional $1 million.
CustomersInvestment
Mirror Biologics Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 9 |
| Team members | 1 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 9 classification IDs that could be used for matching.
Mirror Biologics Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 97/100 |
| Missing | video or image, markets |
| BI Verification | Sharon Shapira |
| Registrar ID | 513529792 |
| Crunchbase | immunovative-therapies |
| Phone | +97226505088 |
| Creator | Rebecca Mack |
| Creator email | rebeccamack26@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2023-09-20T00:00:00.000Z |
| Created | 2014-07-31T00:00:00.000Z |